drugset / Trial / NCT06411860
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
RandomizedCrossoverDouble-blindBasic science
Summary
The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.
Timeline
- Start
- 2024-09-12
- Primary completion
- 2024-11-29
- Completion
- 2024-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | — | Oral |
| Subject | Olpasiran | Unknown | — | Subcutaneous |
Indications
No indication recorded.